Introduction
Dementia with Lewy bodies (DLB), which is pathologically characterized by accumulation of Lewy bodies (LB), is the second most common cause of neurodegenerative dementia after Alzheimer's disease (AD) (McKeith et al., 1996) . Early and accurate diagnosis of DLB is essential to enable appropriate treatment and care, in addition to identify and manage clinical features including motor and psychiatric symptoms, severe autonomic dysfunction and hazardous antipsychotic sensitivity (McKeith et al., 2017) . A valid diagnosis is also central for predicting the prognosis of the disease and planning clinical trials, but the diagnostic process may be complicated by substantial overlap in clinical and neuropsychological features between AD and DLB (McKeith et al., 2016) .
Furthermore, the frequent occurrence of pathological heterogeneity in DLB patients, particularly coexisting AD pathology, i.e. amyloid beta (Aβ) plaques and tau tangles, can contribute to diverse clinical presentations (Schneider et al., 2007; van Steenoven et al., 2016) . Aβ pathology in patients with DLB has been associated with faster cognitive decline and shorter survival compared to the DLB patients with pure LB pathology (Donaghy et al., 2015; Irwin et al., 2018) . These findings underline the clinical relevance of identifying coexisting Aβ pathology in DLB patients.
Functional neuroimaging has become a commonly used supplement to the clinical diagnosis of dementia (Vernooij et al., 2019) , and has also been introduced in the diagnostic criteria for both DLB and AD (McKhann et al., 2011; McKeith et al., 2017) . Several studies have demonstrated 2009). CIS is defined as preserved metabolism of the posterior cingulate cortex (PCC) relative to reduced metabolism in the precuneus and the cuneus, and is included in the updated diagnostic DLB criteria (McKeith et al., 2017) . The CIS ratio, defined as the measure of FDG uptake in the PCC divided by the sum of the uptake in the precuneus and the cuneus, is higher in DLB patients compared to AD patients as demonstrated by a semi-quantitative method (Lim et al., 2009; Kantarci et al., 2012a; Graff-Radford et al., 2014; O'Brien et al., 2014; Iizuka and Kameyama, 2016) . A quantitative method can be time consuming, requires standardized acquisition and analysis of both the 18F-FDG-PET and the structural scan, i.e. either computed tomography (CT) or magnetic resonance imaging (MRI), and the specific software may only be accessible in expert centres. Of interest, a dichotomous visual interpretation of CIS (present or absent) had a higher diagnostic accuracy compared to the quantitative CIS ratio in distinguishing DLB patients from AD patients (Lim et al., 2009) . However, there are no established visual criteria for the degree of CIS, even though visual rating of other imaging biomarkers and modalities are commonly used and has proven to be a fast, reliable and reproducible method in clinical practice (Høgh et al., 2007; Wahlund et al., 2017; Vernooij et al., 2019) . The application of a standardized method to classify and interpret the presence of CIS may enhance the utilization of relevant diagnostic information, along with improving the diagnostic accuracy of DLB. Furthermore, a visual rating scale can easily be implemented into the clinical practice across centres and assist the less experienced nuclear medicine physicians. visual features of occipital involvement and forced diagnosis; (4) to examine whether coexisting Aβ pathology influenced the presence of CIS for the DLB patients.
Materials and methods

AD and DLB study population
The study population consisted of retrospectively identified patients with a clinical diagnosis of DLB according to the DLB criteria (McKeith et al., 2005) and AD according to the AD criteria 
Healthy controls
A group of 23 healthy elderly controls aged over 60 years with normal MRI and 18F-FDG-PET results, and normal neuropsychology scores from the Memory Clinic at Rigshospitalet was also included. The controls consisted of 18 healthy research volunteers and five subjects with subjective cognitive decline in whom dementia and neurodegenerative disease had been ruled out. All controls had no evidence of brain amyloid accumulation, i.e. normal concentration of Aβ42 in CSF, except three of the healthy research volunteers who did not undergo assessment of brain amyloid.
All healthy research volunteers gave a written informed consent, and the inclusion was approved by the Danish National Committee on Health Research (no. H-1-2014-126).
Clinical examinations
All patients and controls underwent a standardized diagnostic dementia assessment including medical history, physical and neurological examinations, cognitive testing (i.e. Mini mental state examination (MMSE) and Addenbrooke's cognitive examination), routine blood screening, and a structural scan, i.e. either CT or MRI.
The dementia patients were followed up longitudinally as part of the standard clinical routine, and 93 % of the patients were followed for at least 12 months. Fujirebio, Europe, Ghent, Belgium). An abnormal Aβ42 (< 550 pg/mL) was indicated as Aβ+, whereas a normal Aβ42 was indicated as Aβ− (Zwan et al., 2016).
Imaging
Imaging was performed over a seven-year period at different hospitals using a range of scanner systems. General aspects of MRI, 123I-FP-CIT-DAT-SPECT, 11C-PiB-PET, and 18F-FDG-PET imaging are summarized in subsection 2.4.1-2.4.5. Imaging details are provided in Appendix A.
Acquisition of MRI
MRI was performed on a clinical 1.5 or 3.0 Tesla system. A high-resolution 3D T1 weighted MRI sequence suitable for tissue segmentation was available in 77 subjects. A semi-quantitative CIS ratio analysis of the high-resolution 3D T1 weighted MRI sequence was performed as describe in subsection 2.4.5.
Analysis of 123I-FP-CIT-DAT-SPECT
A visual interpretation of reduced symmetric or asymmetric tracer uptake in putamen and/or caudate nucleus was defined as abnormal, supported by the semiquantitative analysis of the specific binding ratio of striatum, caudate nucleus, and putamen relative to occipital cortex and the putamen/caudate nucleus uptake ratio (Darcourt et al., 2010; McCleery et al., 2015) .
Analysis of 11C-PiB-PET
A visual interpretation of increased tracer uptake in at least two cortical AD specific regions at the level of or above white matter supported by cortex-to-cerebellar grey matter uptake ratio > 1.5 was defined as abnormal (Minoshima et al., 2016 ). An abnormal 11C-PiB-PET was indicated as Aβ+, whereas a normal 11C-PiB-PET was indicated as Aβ−.
Acquisition of 18F-FDG-PET
J o u r n a l P r e -p r o o f Journal Pre-proof The PET imaging was performed according to the international practice guideline (Varrone et al., 2009 ). PET images were acquired using clinical PET/CT or PET/MRI systems after an intravenous bolus of 200-300 MBq 18F-FDG as a 10 min static scan during the 40-60 min post-injection time window. All images were reconstructed using CT based attenuation correction (Andersen et al., 2014) .
Analysis of 18F-FDG-PET
Analysis of quantitative CIS ratio: The high-resolution 3D T1 weighted MRI sequence was segmented using FreeSurfer (version 5.3.0) (Fischl, 2012) to generate region of interests (ROIs) of PCC, precuneus, cuneus, and cerebellar grey matter for each hemisphere based on the Desikan-Killiany Atlas. The 18F-FDG-PET image of each patient was fused to the segmented MRI and the mean ROI values were obtained. Only non-partial volume corrected PET data was used, as partial volume corrected by the Symmetric Geometric Transfer Matrix method (Greve et al., 2016) was not sufficiently robust. The mean standardized uptake value (SUV) of each region was normalized to cerebellum. In each hemisphere the ratio for the mean SUV in the PCC ROI was divided by the mean SUV in the combined precuneus plus cuneus ROIs, the quantitative CIS ratio was derived by averaging the ratios for each hemisphere (Lim et al., 2009) . Standardized reading approach for the visual CIS-scale: A standard reading approach was used to standardize the 18F-FDG-PET images and optimize the visualization of the CIS region (Figure 1) :
Standardized reading approach for the visual interpretation:
 the 18F-FDG-PET scan was displayed on a clinical workstation using SyngoVia with the PET image superimposed on the structural scan.
 the scan was displayed in "PET Rainbow" and windowing adjusted to basal ganglia red and cerebellum green/yellow with red hues.
 three-way orthogonal view approximately along AC-PC plane with both sagittal and axial planes through PCC, precuneus, and cuneus. The visual CIS scoring was based on both sagittal and axial views.
Scoring of the visual CIS scale: First, the degree of hypometabolism in PCC, precuneus, and cuneus was classified for each hemisphere as "none", "mild", or "moderate-to-severe".
Secondly, the presence of CIS was based on the degree of hypometabolism in PCC, precuneus, and cuneus together with a visual, interpretation of CIS including influence of central or cortical atrophy, and rated for each hemisphere according to the following criteria: If the activity uptake in precuneus or cuneus was considered reduced because of adjacent leukoaraiosis or ischemia on the available structural scan the rating was changed to 0.
Finally, the ratings from each hemisphere were summed to a visual CIS score. Three examples of scorings of the visual CIS scale are giving in Figure 2 .
For clinical operationalization the visual CIS score was classified as: Score 0 = "no CIS" Score 1-2 = "possible CIS" Score 3-4 = "definite CIS"
Occipital hypometabolism: Occipital hypometabolism was assessed in lateral and medial occipital cortices and rated as "present" or "absent".
Forced diagnosis: This approach was adopted to mimic the usual reading approach of a nuclear medicine physician. The forced diagnosis was based on the overall visual interpretation of the 18F-FDG-PET scan including typical features of DLB (predominant occipital involvement with no or 3). In comparison, the optimal cut-off value of ≥ 0.98 on the quantitative CIS ratio separated DLB patients and AD patients with a higher sensitivity of 88% and a lower specificity of 67%, yielding a balanced accuracy of 77%. When comparing the performance of the two methods by an AUC analysis, we observed no significant difference (p = 0.45) in differentiating DLB patients and AD patients, although the latter method had a slightly better performance. Also, the visual CIS scale did not differ in performance when compared with visual interpretation of occipital hypometabolism and forced diagnosis for distinguishing DLB patients and AD patients (Table 3) .
Amyloid positive and amyloid negative DLB patients
The DLB Aβ− patients had the highest median visual CIS score of 4, followed by DLB Aβ+ patients with a median score of 1, and lastly the AD patients with a median score of 0. However, the visual CIS score were only significant different between the AD patients and the DLB subgroups, although the difference between DLB Aβ+ patients and DLB Aβ− patients reached a trend level of p = 0.06. A significant larger proportion of the DLB Aβ− patients (58%) was classified with "definite CIS", when compared both to DLB Aβ+ patients (25%) and to AD patients (3%) ( Table   2 ). Table 3 , an optimal cut-off score of 4 on the visual CIS scale distinguish DLB Aβ− patients from the DLB Aβ+ patients and AD patients with a balanced accuracy of 70% and 80% respectively. When applying the Fishers exact test, the proportion of DLB Aβ− patients with a visual CIS score 4 was significantly higher compared to the DLB Aβ+ patients and AD patients.
As shown in
The original study introducing visual interpretation of CIS for differentiating DLB from AD by Lim et al. found CIS to be highly specific for DLB with a specificity of 100% and a sensitivity ranging from 62% to 86% (Lim et al., 2009 ). The higher diagnostic accuracy in the prior study compared to our findings may be due to a restricted dichotomized rating of CIS in a relatively small study cohort of 14 DLB patients and 10 AD patients, together with only 29% of DLB patients having AD pathology. In contrast, we aimed to characterize the degree of CIS in the pathological heterogenous DLB patients considering previous studies have demonstrated higher CIS ratio in DLB patients compared to AD patients (Lim et al., 2009; Kantarci et al., 2012a; Graff-Radford et al., 2014; O'Brien et al., 2014; Iizuka and Kameyama, 2016) together with over half of pathologically confirmed DLB cases have coexisting AD pathology (Barker et al., 2002; Fujishiro et al., 2010) .
We evaluated the performance of the visual CIS scale against a quantitative CIS method as the presence of CIS has mainly been demonstrated by various quantitative methods (Lim et al., 2009; Kantarci et al., 2012a; Graff-Radford et al., 2014; O'Brien et al., 2014; Iizuka and Kameyama, 2016; Whitwell et al., 2017) . In accordance with the previous studies, we found a significantly higher quantitative CIS ratio for the DLB patients compared to the AD patients and controls (Table   2 ). The visual CIS scale had a similar diagnostic accuracy compared to the quantitative CIS ratio in distinguishing DLB patients from AD patients, but from a clinical perspective a visual rating scale is advantageous compared to a quantitative method for several reasons. A quantitative method can be time consuming, the actual value depends on both the acquisition and processing of the 18F-FDG-PET and MRI, and the specific software used may only be accessible in expert centres. A cutoff value may thus only be applicable to a specific setup in a single centre. In contrast, a visual rating scale for CIS can be implemented as a fast-diagnostic adjunct to the standard visual 18F-FDG-PET scan evaluation without additional software.
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The visual CIS scale was also compared to another relevant 18F-FDG-PET feature (occipital hypometabolism) and to an overall visual evaluation of the 18F-FDG-PET image including typical and atypical features of DLB and AD (forced diagnosis). The performance for these 18F-FDG-PET visual features in distinguishing DLB from AD were consistent with two previous studies of similar ratings (Lim et al., 2009; O'Brien et al., 2014) , and comparable to the visual CIS scale. This suggests that the visual CIS scale may supplement or even replace more resource demanding techniques performed by experienced nuclear medicine physicians.
Finally, we examined if the presence of CIS was influenced by concurrent Aβ pathology in DLB patients. Comparable to previous studies (Edison et al., 2008; Kantarci et al., 2012b) , we found that nearly half (46%) of the patient with a clinical diagnosis of DLB had an abnormal Aβ biomarker (Aβ+). Two previous studies consisting of a smaller study of 10 DLB patients (Ishii et al., 2015) and a larger study of 39 DLB patients (Graff-Radford et al., 2014) with determination of the brain Aβ status by 11C-PiB-PET found no association between a quantitative method of CIS and Aβ accumulation. Likewise, we found no significant differences between the DLB Aβ− patients and DLB Aβ+ patients for the quantitative CIS ratio. However, we found that the DLB Aβ− patients had the highest score on the visual CIS scale in comparison to the DLB Aβ+ patients with intermediate values (Table 2) as an indication of coexisting Aβ pathology may diminish the presence of CIS, although the difference only reached a trend level of p = 0.06.
Additionally, a cut-off visual CIS score of 4 discriminated the DLB Aβ − patients from DLB Aβ+ patients with a balanced accuracy of 70%, and this finding corroborate that Aβ pathology might be a possible confounding factor associated with the presence of CIS in DLB patients, which is relevant to include in the interpretation of CIS.
In general, the visual CIS scale distinguishes the diagnostic groups (DLB and AD) and the subgroups (DLB Aβ−, DLB Aβ+, and AD) with high specificities, but only moderate sensitivities.
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Journal Pre-proof This may be explained by various potentially confounding circumstances. Previous studies have suggested that CIS may be influenced by the severity of cognitive impairment (Graff-Radford et al., 2014; Morbelli et al., 2019) , however, in line with a previous study (Iizuka and Kameyama, 2016), we did not find a relationship between CIS and MMSE. The implementation of the visual CIS scale in a routine practice is potentially valuable considering that visual features including cingulate hypometabolism seemed to be underreported and missed on the clinical interpretation of FDG-PET scans of patients with DLB (Hamed et al., 2018) .
Combining the visual CIS scale on 18F-FDG-PET with visual assessment of atrophy pattern on MRI (Oppedal et al., 2019) could potentially increase the accuracy of DLB diagnosis and could be explored in future studies. Furthermore, the visual CIS scale should preferably be evaluated in a larger mixed memory cohort with unknown diagnosis and by less experienced readers. Some limitations should be considered. In this study, the diagnosis of DLB and AD lacked pathological confirmation, but the reference diagnosis was based on reconfirmed diagnosis by an experienced dementia specialist (SGH, AH, and PH) according to the current DLB diagnostic criteria (McKeith et al., 2005) and AD research criteria (McKhann et al., 2011) , and based on all available data including clinical follow up for at least 12 months for the majority of the patients.
Another limitation is the selection criteria, considering that we only included DLB patients with an Aβ biomarker and a 123I-FP-CIT-DAT-SPECT and AD patients with an Aβ biomarker, respectively, which are considered as supplementary disease biomarkers if the diagnosis is questionable in our clinics. Consequently, our study population may consist of patients with a more heterogenous clinical presentation, which may diminish the diagnostic accuracy. A final limitation is the use of different scanners given that the diagnostic workup for the study population was performed across several centres. On the other hand, visual ratings are in general more robust for scanner differences and should be applicable without consideration of the scanner. J o u r n a l P r e -p r o o f Abbreviations: Aβ = amyloid beta; AD = Alzheimer's disease; AUC = the area under the receiver operating characteristic curve; Bal. acc. = balanced accuracy; CI = confidence interval; CIS = cingulate island sign; DLB = dementia with Lewy bodies; Sens. = sensitivity; Spec. = specificity; 
